Soft-tissue sarcomas are rare malignant tumors arising from connective tissues and have an
overall incidence of about five per 100,000 per year. While this diverse family of …

Soft tissue sarcoma (STS) is a biologically heterogeneous malignancy with over 50
subtypes. Historically, there have been few systemic treatment options for this relatively rare …

Purpose Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an
oral angiogenesis inhibitor that targets vascular endothelial growth factor receptor and …

Pazopanib (Votrient®) is an oral small-molecule multi-kinase inhibitor that primarily inhibits
vascular endothelial growth factor receptor-1,-2 and-3, platelet endothelial growth factor …

Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelio... : Current Opinion in
Oncology Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelioid …

Pazopanib is an oral, multi-targeted, tyrosine kinase inhibitor (TKI) that binds to the vascular
endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) …

The growth and dissemination of sarcomas depends on angiogenesis. A number of
measurable markers related to tumor angiogenesis have been studied in patients with …

Soft tissue sarcomas (STS) represent a diverse group of histologic subtypes with targetable
molecular alterations, often treated as a single disease. Sunitinib malate is a multitargeted …

Due to the rarity and heterogeneity of bone and soft-tissue sarcomas, investigation into
molecular targets and new treatments has been particularly challenging. Although intensive …

BACKGROUND This phase 2, single‐arm, multicenter study was designed to determine the
treatment activity and safety of single‐agent pazopanib in patients with unresectable or …